Lung cancer is a leading cause of cancer-related deaths with an increasing incidence and poor prognoses. To further understand the regulatory mechanisms of lipidomic profiles in lung cancer subtypes, we measure the profiles of plasma lipidome between health and patients with lung cancer or among patients with squamous cell carcinomas, adenocarcinoma or small cell lung cancer and to correct lipidomic and genomic profiles of lipid-associated enzymes and proteins by integrating the data of large-scale genome screening. Our studies demonstrated that circulating levels of PS and lysoPS significantly increased, while lysoPE and PE decreased in patients with lung cancer. Our data indicate that lung cancer-specific and subtype-specific lipidomics in the circulation are important to understand mechanisms of systemic metabolisms and identify diagnostic biomarkers and therapeutic targets. The carbon atoms, dual bonds or isomerism in the lipid molecule may play important roles in lung cancer cell differentiations and development. This is the first try to integrate lipidomic data with lipid protein-associated genomic expression among lung cancer subtypes as the part of clinical trans-omics. We found that a large number of lipid proteinassociated genes significantly change among cancer subtypes, with correlations with altered species and spatial structures of lipid metabolites.
Systems heterogeneity of lung cancer was described by integrating gene or protein expression, epigenetics, sequencing, transcription or interaction. 2 Of those, there are a few studies on the heterogeneity of lipidomic profiles among lung diseases, which play an important role in the development, evolution, metabolism and mechanic function of lung. Marien et al Each experiment was repeated thrice. MRM data were processed with MultiQuant ™ software (AB Sciex), and peak area of each pair was used for further quantification. Lung cancer specificity was identified to compare the pooled group of all subtypes with the health.
The subtype specificity was defined as the level significantly higher or lower than that in the health (>twofold and P < 0.05), but not in other subtypes.
It was firstly reported that circulating levels of PS and lysoPS significantly increased, while lysoPE and PE decreased in patients with lung cancer. Our data demonstrated that the circulating levels of PE40s or lysoPE20s lipid species were significantly higher or lower in patients with lung cancer, respectively, of which about 28 lipid T A B L E 1 Up-or down-regulated type-special lipids in serum over twofold in adenocarcinoma (ADC), squamous cell carcinoma (SCC) or small cell lung cancer (SCLC)
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Up-regulated type-special lipids in SCC PA and PG on lung cancer cell surfaces. 10 The changed serum levels of phospholipids and their derivatives, e.g lysophosphatidylcholines and lysophosphatidylethanolamine, are considered as promising cancer markers. 9, 11 On basis of previous finding that plasma level of the LPC reduced in patients with lung cancer and colorectal cancer, 12 our results furthermore evidenced that lysoPG and lysoPI are lower in the plasma of patients with lung cancer than healthy individuals.
Lipid synthesis and its metabolites were suggested as a metabolic liability and potential biomarkers of lung cancer. 13 Lipidome varied between the health and patients with lung cancer or among subtypes implies the existence of lipidomic heterogeneity, which may be caused by local and systemic cell metabolism and inflammation. To further understand the regulatory mechanisms of lipidomic profiles in lung cancer subtypes, we mined the genomic profiles of lipidassociated enzymes and proteins from the global database integrated the data of large-scale genome screening and other large mutation databases, as reported previously. 14 We found that a large number of lipid protein-associated genes significantly change among cancer subtypes, with correlations with altered species and spatial struc-
